PURPOSE: The purpose of this study was to investigate naturally occurring C-peptide microheterogeneity in healthy and type 2 diabetes (T2D) populations. EXPERIMENTAL DESIGN: MS immunoassays capable of simultaneously detecting intact C-peptide and variant forms were applied to plasma samples from 48 healthy individuals and 48 individuals diagnosed with T2D. RESULTS: Common throughout the entire sample set were three previously unreported variations of C-peptide. The relative contribution of one variant, subsequently identified as C-peptide (3-31), was found to be more abundant in the T2D population as compared to the healthy population. Dipeptidyl peptidase IV is suspected to be responsible for this particular cleavage product, which is consistent with the pathophysiology of T2D. CONCLUSIONS AND CLINICAL RELEVANCE: C-peptide does not exist in the human body as a single molecular species. It is qualitatively more heterogeneous than previously thought. These results lay a foundation for future studies devoted to a comprehensive understanding of C-peptide and its variants in healthy and diabetic populations.
PURPOSE: The purpose of this study was to investigate naturally occurring C-peptide microheterogeneity in healthy and type 2 diabetes (T2D) populations. EXPERIMENTAL DESIGN: MS immunoassays capable of simultaneously detecting intact C-peptide and variant forms were applied to plasma samples from 48 healthy individuals and 48 individuals diagnosed with T2D. RESULTS: Common throughout the entire sample set were three previously unreported variations of C-peptide. The relative contribution of one variant, subsequently identified as C-peptide (3-31), was found to be more abundant in the T2D population as compared to the healthy population. Dipeptidyl peptidase IV is suspected to be responsible for this particular cleavage product, which is consistent with the pathophysiology of T2D. CONCLUSIONS AND CLINICAL RELEVANCE: C-peptide does not exist in the human body as a single molecular species. It is qualitatively more heterogeneous than previously thought. These results lay a foundation for future studies devoted to a comprehensive understanding of C-peptide and its variants in healthy and diabetic populations.
Authors: Diego Rodríguez Cabaleiro; Dietmar Stöckl; Jean M Kaufman; Tom Fiers; Linda M Thienpont Journal: Clin Chem Date: 2006-04-13 Impact factor: 8.327
Authors: R P Pauly; H U Demuth; F Rosche; J Schmidt; H A White; F Lynn; C H McIntosh; R A Pederson Journal: Metabolism Date: 1999-03 Impact factor: 8.694
Authors: K S Polonsky; B D Given; L Hirsch; E T Shapiro; H Tillil; C Beebe; J A Galloway; B H Frank; T Karrison; E Van Cauter Journal: J Clin Invest Date: 1988-02 Impact factor: 14.808
Authors: Paul E Oran; Jason W Jarvis; Chad R Borges; Nisha D Sherma; Randall W Nelson Journal: Proteomics Clin Appl Date: 2011-06-08 Impact factor: 3.494
Authors: Chad R Borges; Paul E Oran; Sai Buddi; Jason W Jarvis; Matthew R Schaab; Douglas S Rehder; Stephen P Rogers; Thomas Taylor; Randall W Nelson Journal: Clin Chem Date: 2011-03-14 Impact factor: 8.327
Authors: Bryan Krastins; Amol Prakash; David A Sarracino; Dobrin Nedelkov; Eric E Niederkofler; Urban A Kiernan; Randall Nelson; Maryann S Vogelsang; Gouri Vadali; Alejandra Garces; Jennifer N Sutton; Scott Peterman; Gregory Byram; Bruno Darbouret; Joëlle R Pérusse; Nabil G Seidah; Benoit Coulombe; Johan Gobom; Erik Portelius; Josef Pannee; Kaj Blennow; Vathany Kulasingam; Lewis Couchman; Caje Moniz; Mary F Lopez Journal: Clin Biochem Date: 2013-01-08 Impact factor: 3.281
Authors: Alexander V Stoyanov; Eduard Rogatsky; Daniel Stein; Shawn Connolly; Curt L Rohlfing; Randie R Little Journal: Proteomics Clin Appl Date: 2013-10-18 Impact factor: 3.494
Authors: Hussein Yassine; Chad R Borges; Matthew R Schaab; Dean Billheimer; Craig Stump; Peter Reaven; Serrine S Lau; Randall Nelson Journal: Proteomics Clin Appl Date: 2013-07-09 Impact factor: 3.494